8-K current report · filed Nov 13, 2026

OptimizeRx Corp (OPRX) 8-K Current Report: November 13, 2026

Item 2.02Item EX-99.2Item EX-99.1OPRX overview

Short answer

OptimizeRx Corp (OPRX) filed an 8-K current report with the SEC on November 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 results for quarter ended September 30, 2026 announced November 11, 2026.

OptimizeRx Corp 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 results for quarter ended September 30, 2026 announced November 11, 2026
  • Updated 2026 revenue guidance, signaling revised management expectations
  • Press release and investor conference call transcript available in Exhibits 99.1 and 99.2

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue fell 17% to $21.6 million, signaling continued weakness in in-year pharmaceutical contract demand
  • Adjusted EBITDA rose to $6.3 million from $5.1 million, with margin expansion offsetting lower revenue through product mix and cost controls
  • FY2026 revenue guidance reduced to $87-$93 million, while adjusted EBITDA guidance held at $21-$25 million
  • Net revenue retention declined to 83% from 121%, and average revenue per top-20 manufacturer fell to $2,504 from $3,087
  • Debt principal reduced to $10.4 million after $9.3 million repaid since June 30, supported by $12.9 million nine-month operating cash flow

Item EX-99.2 · Exhibit EX-99.2

  • Q3 revenue $21.6M, down 17% YoY, while Adjusted EBITDA rose to $6.3M from $5.1M
  • Adjusted EBITDA margin approximately 29%, up more than 900 basis points, signaling substantial operating leverage despite weaker sales
  • FY2026 revenue guidance reduced to $87M-$93M, with Q4 execution risk elevated as contracted revenue runs approximately 20% below prior year
  • FY2026 Adjusted EBITDA guidance maintained at $21M-$25M, supported by low-70% expected gross margin and cost reductions
  • Liquidity strengthened through $9M additional debt paydown, reducing debt to $10.4M after quarter-end at SOFR plus 2.25%

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other OptimizeRx Corp 8-K filings

Get the next OPRX 8-K as it lands

Follow OPRX for push alerts, or ask the research agent what this filing means.